BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Paskeh MDA, Mehrabi A, Gholami MH, Zabolian A, Ranjbar E, Saleki H, Ranjbar A, Hashemi M, Ertas YN, Hushmandi K, Mirzaei S, Ashrafizadeh M, Zarrabi A, Samarghandian S. EZH2 as a new therapeutic target in brain tumors: Molecular landscape, therapeutic targeting and future prospects. Biomed Pharmacother 2021;146:112532. [PMID: 34906772 DOI: 10.1016/j.biopha.2021.112532] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Taheriazam A, Abad GGY, Hajimazdarany S, Imani MH, Ziaolhagh S, Zandieh MA, Bayanzadeh SD, Mirzaei S, Hamblin MR, Entezari M, Aref AR, Zarrabi A, Ertas YN, Ren J, Rajabi R, Paskeh MDA, Hashemi M, Hushmandi K. Graphene oxide nanoarchitectures in cancer biology: Nano-modulators of autophagy and apoptosis. J Control Release 2023;354:503-22. [PMID: 36641122 DOI: 10.1016/j.jconrel.2023.01.028] [Reference Citation Analysis]
2 McClellan BL, Haase S, Nunez FJ, Alghamri MS, Dabaja AA, Lowenstein PR, Castro MG. Impact of epigenetic reprogramming on antitumor immune responses in glioma. J Clin Invest 2023;133. [PMID: 36647827 DOI: 10.1172/JCI163450] [Reference Citation Analysis]
3 Hashemi M, Mirzaei S, Zandieh MA, Rezaei S, Amirabbas Kakavand, Dehghanpour A, Esmaeili N, Ghahremanzade A, Saebfar H, Heidari H, Salimimoghadam S, Taheriazam A, Entezari M, Ahn KS. Long non-coding RNAs (lncRNAs) in hepatocellular carcinoma progression: Biological functions and new therapeutic targets. Prog Biophys Mol Biol 2022:S0079-6107(22)00132-8. [PMID: 36584761 DOI: 10.1016/j.pbiomolbio.2022.12.004] [Reference Citation Analysis]
4 Scuderi SA, Filippone A, Basilotta R, Mannino D, Casili G, Capra AP, Chisari G, Colarossi L, Sava S, Campolo M, Esposito E, Paterniti I. GSK343, an Inhibitor of Enhancer of Zeste Homolog 2, Reduces Glioblastoma Progression through Inflammatory Process Modulation: Focus on Canonical and Non-Canonical NF-κB/IκBα Pathways. Int J Mol Sci 2022;23. [PMID: 36430394 DOI: 10.3390/ijms232213915] [Reference Citation Analysis]
5 An R, Li Y, Lin Y, Xu F, Li M, Liu Z. EZH1/2 as targets for cancer therapy. Cancer Gene Ther 2022. [DOI: 10.1038/s41417-022-00555-1] [Reference Citation Analysis]
6 Hashemi M, Hajimazdarany S, Mohan CD, Mohammadi M, Rezaei S, Olyaee Y, Goldoost Y, Ghorbani A, Mirmazloomi SR, Gholinia N, Kakavand A, Salimimoghadam S, Ertas YN, Rangappa KS, Taheriazam A, Entezari M. Long non-coding RNA/epithelial-mesenchymal transition axis in human cancers: Tumorigenesis, chemoresistance, and radioresistance. Pharmacological Research 2022. [DOI: 10.1016/j.phrs.2022.106535] [Reference Citation Analysis]
7 Chen X, Chen Y, Chen X, Wei P, Lin Y, Wu Z, Lin Z, Kang D, Ding C. Single-cell RNA sequencing reveals intra-tumoral heterogeneity of glioblastoma and a pro-tumor subset of tumor-associated macrophages characterized by EZH2 overexpression. Biochim Biophys Acta Mol Basis Dis 2022;:166534. [PMID: 36057370 DOI: 10.1016/j.bbadis.2022.166534] [Reference Citation Analysis]
8 Sadrkhanloo M, Entezari M, Rashidi M, Hashemi M, Raesi R, Saghari S, Daneshi S, Salimimoghadam S, Hushmandi K, Mirzaei S, Taheriazam A. Non-coding RNAs in EMT regulation: Association with tumor progression and therapy response. European Journal of Pharmacology 2022. [DOI: 10.1016/j.ejphar.2022.175212] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Nanamori H, Sawada Y. Epigenetic Modification of PD-1/PD-L1-Mediated Cancer Immunotherapy against Melanoma. Int J Mol Sci 2022;23:1119. [PMID: 35163049 DOI: 10.3390/ijms23031119] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]